Molbank
2008, M574
molbank
ISSN 1422-8599
www.mdpi.org/molbank
Short Note
Synthesis, Characterization and
Antileucemic Activity of
7-Hydroxy-8-acetylcoumarin Benzoylhydrazone
Antigoni Kotali 1,*,
Ioannis S. Lafazanis, Athanassios Papageorgiou 2, Eleni
Chrysogelou 2, Theodoros Lialiaris 3, and Zacharias
Sinakos 4
1 Laboratory of Organic
Chemistry, Department of Chemical Engineering, College of Engineering,
University of Thessaloniki, Thessaloniki 54006, Greece E-mail: [email protected]
2 Department of Experimental Chemotherapy, Symeonidion Research Center, Theagenion Cancer Hospital, Thessaloniki 54007, Greece
3 Department of Genetics, Democritus University of Thrace, Alexandroupolis, Greece
4 EKETA, Thessaloniki 57001, Greece
* Author to whom correspondence should be addressed.
Received:
24 April 2007; in revised form: 8 August 2008 /
Accepted: 18 August 2008 / Published: 24
August 2008
Keywords: 7-Hydroxy-8-acetylcoumarin,
benzoic hydrazide.
As part of a research programme targeting
novel molecules derived from nitrogen derivatives of o-hydroxyaryl
ketones [1] we synthesised 7-hydroxy-8-acetylcoumarin
benzoylhydrazone. Coumarins are very well known for their biological
activity [2]. Moreover hydrazone moiety has been reported to possess anticancer
activity [3]. Thus, it is not unreasonable to assume that a molecule that
possesses both coumarin and hydrazone features will possibly show interesting
combined biological activity.
7-Hydroxy-8-acetylcoumarin was prepared according to the literature method [4]
whereas commercially available benzoic hydrazide was supplied by Aldrich.
1. Method of
Preparation 7-hydroxy-8-acetylcoumarin benzoylhydrazone
Benzoic hydrazide (0.61
g, 4.5 mmol) was added to a solution of 7-hydroxy-8-acetylcoumarin (1 g, 4.5
mmol) in propanol-1 (10 mL). The
reaction mixture was refluxed for 24 hours. It was then allowed to cool at room
temperature. Subsequently, it was stored in the refrigerator overnight. Filtration
of the precipitate, which was formed, afforded (1.38 g, 92 %) of the desired N-benzoylhydrazone
as white crystals. The product was identified by its 1H NMR, 13C
NMR and MS and it was subjected to elemental analysis without further
purification.
M.p. 248.5-249.5 °C.
1H NMR (400 MHz, DMSO-d6):
2.28 (s, 3H), 6.25-6.25 (d, J=8.6Hz, 1H),
6.93-6.95 (d, J=8.6Hz, 1H), 7.41-8.08
(m, 4H), 8.57-8.80 (m, 3H), 11.24 (s, 1H), 12.37 (s, 1H).
13C NMR (100 MHz, DMSO-d6):
19.6, 111.9, 112.0, 112.45, 114.4, 120.0, 123.8, 129.1, 130.7, 132.55, 133.9,
137.9, 145.6, 154.0, 154.9, 160.5, 160.9, 165.2.
MS m/z
(ES+): 345 [M+Na]+, 323 [M+1]+.
Anal. Calc. for C18H14N2O4:
C 67.08, H 4.38, N 8.69; found: C 66.99, H 4.30, N, 8.61.
2. Material and
Methods
2.1. Mice
Male and female mice DBA/2
and BDF1 (C57Bl6 x DBA/2) mice that were 4-6 weeks of age and
weighted 20-25 g were used for toxicity and antitumor evaluation experiments. Mice,
provided by the Experimental Animal production Laboratory of Theagenion Cancer Hospital,
were under conditions of constant temperature and humidity, with sterile
beckling, water and food.
2.2. Tumor
Transplantation of lymphocytic
P388 Leucemia was carried out by withdrawing peritoneal fluid from donor DBA/2
mice with 7-day growth. The suspension was centrifuged for 2 min (2000 g). The
supernatant peritoneal fluid was decanted and a fold dilution with 0.9% NaCl
solution was made. The cell number was determined. The resulting cell
suspension of 0.1 ml, containing 106 cells, was injected intraperitoneally into
each animal.
2.3. Compounds
In
all experiments, 7-hydroxy-8-acetylcoumarin
benzoylhydrazone was administrated by IP injection. It was dissolved in 10%
DMSO and suspended in corn oil. Stock solutions of the compound were prepared
immediately before administration.
Percentage of deaths due to the toxicity of each dose
is plotted on the ordinate, while the administered doses are plotted on the
abscisae on semilogarithmic paper. The point of the line corresponding to 50%
and 10% mortalities gives the L50 and L10 respectively [5].
3. Chemotherapy Evaluation
For the survival
experiments, the antitumor activity of 7-hydroxy-8-acetylcoumarin
benzoylhydrazone against P388 murine lymphocytic leukaemia was assessed from
the oncostatic parameter T/C% : the mean of median survival time of the
drug-treated animals (T) excluding long-term survivors, versus corn-oil treated
controls (C), expressed as percentage. The minimum criterion for activity is
T/C≥125%, according to the experimental evaluation of antitumor drugs in
National Cancer Institute in USA [6].
4. Acute
Toxicity
All experiments were
consisted of six mice in each drug treatment group and eight mice in the tumor
control group. Experiments were initiated by implanting mice with tumor cells.
Drug treatments were given as single, or intraperitoneally injections, using LD40
as a therapeutic dose. Experiments were terminated when no mice remained alive
[5].
5. Results
The
results for the antileucemic activity of 7-hydroxy-8-acetylcoumarin
benzoylhydrazone are presented in Table I.
From the Table I it can be seen that the antitumor activity of 7-hydroxy-8-acetylcoumarin benzoylhydrazone is interesting producing T/C rates of 147 and 138% when the single and intermitted (days 1,4,7) treatment schedules, respectively, were used. This activity is above the borderline activity (T/C≥125%), which is the minimum criterion of activity of drugs [5].
Table 1. Antitumer Activity of 7-hydroxy-8-acetylcoumarin benzoylhydrazone in murine P388 leukemia.
Treatment Schedule |
Dosage(mg/kg) |
MSTa(days) |
T/C%b |
200 |
Day 1 |
13.25 (9.0)c |
147 |
100 |
Days 1,4,7 |
14.5 (10.5)c |
138 |
100 |
Days 1-9 |
10.4 (9.0)c |
116 |
aMST: survival time
bT/C: survival time of drug-treated animals (T) versus
corn-oil control animals (C)
cMST of control animals
References
1. |
Kotali, A.; Harris,
P. A. Org. Prep. Proc. Int. 1994, 26(2), 155. |
|
2. |
O’Kennedy R.; Thornes R. D. Coumarins: Biology, Applications and Mode of Action; John Wiley: England, 1997. |
|
3. |
Abdel-Rahman R. M.; Seada M.; Fawzy M.; el-Baz I. Farmaco. 1993, 48(3), 397. |
|
4. |
Abramov, M. A.;
Dehaen, W. Synthesis 2000, 11, 1529. |
|
5. |
EORTC group. EORTC screening procedures. Eur. J. Cancer 1972, 8, 185. |
|
6. |
Goldin, A; Sofivia, Z.; Syruin, A. National Cancer Insitute Monograph 1980, 55. |
© 2008 by the authors; licensee Molecular
Diversity Preservation International, Basel, Switzerland. This article is an
open-access article distributed under the terms and conditions of the Creative
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).